Currently, Capricor Therapeutics Inc [CAPR] is trading at $14.23, up 7.97%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CAPR shares have gain 43.88% over the last week, with a monthly amount glided 106.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Capricor Therapeutics Inc [NASDAQ: CAPR] stock has seen the most recent analyst activity on May 20, 2025, when Roth Capital initiated its Buy rating and assigned the stock a price target of $31. Previously, Piper Sandler started tracking the stock with Overweight rating on October 21, 2024, and set its price target to $35. On May 17, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $14 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $8 on January 05, 2024. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $15 as its price target on October 26, 2022. Maxim Group downgraded its rating to Hold for this stock on December 26, 2018. In a note dated January 26, 2018, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $6.50 to $8.60.
This stock has fluctuated between a low of $3.52 and a high of $23.40 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $15.38 within the next 12 months. Capricor Therapeutics Inc [NASDAQ: CAPR] shares were valued at $14.23 at the most recent close of the market. An investor can expect a potential return of 8.08% based on the average CAPR price forecast.
Analyzing the CAPR fundamentals
Trailing Twelve Months sales for Capricor Therapeutics Inc [NASDAQ:CAPR] were 17.36M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -3.3%, Pretax Profit Margin comes in at -3.17%, and Net Profit Margin reading is -3.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.62 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.24 points at the first support level, and at 12.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.79, and for the 2nd resistance point, it is at 15.34.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Capricor Therapeutics Inc [NASDAQ:CAPR] is 6.55. As well, the Quick Ratio is 6.55, while the Cash Ratio is 1.29. Considering the valuation of this stock, the price to sales ratio is 37.47, the price to book ratio is 5.09.
Transactions by insiders
Recent insider trading involved Nippon Shinyaku Co Ltd, 10% Owner, that happened on Sep 20 ’24 when 2.8 million shares were purchased.
